Mallinckrodt: The Rebound Continues

Sell-side analysts continue to defend drug maker Mallinckrodt ’s ( MNK ) shares on the heel of Citron Research’s report on the company released last week. Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a “misunderstood situation creates opportunity.”